1 week ago
24
ARTICLE AD BOX
Alzheimer's disease (AD) remains one of the most pressing global health challenges, especially as aging populations continue to grow. The condition steadily erodes memory and thinking abilities, deeply affecting daily life. New treatments, including monoclonal antibodies such as lecanemab and donanemab, have offered some optimism by slowing cognitive decline. However, these therapies still fall short of reversing the disease or restoring normal brain function.
English (US) ·